NCT06680115View on ClinicalTrials.gov

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG

Sintilimab

Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine

Trial Locations (1)

530021

The First Affiliated Hospital of Guangxi Medical University, Nanning

All Listed Sponsors

lead

First Affiliated Hospital of Guangxi Medical University

OTHER

NCT06680115 - Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter